EVLO — Evelo Biosciences, Inc.
$0.00
+$0.00 (+0.00%)
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis.
Market Cap
$1898.00
Forward P/E
-0.0x
52-Week Range
N/A
EVLO Price History
Revenue vs. Net Income
$0
Revenue · FY2022
Annual. Net margin is shown under each year.
Free Cash Flow
-$102M
FCF · FY2022
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-209.3%
ROCE · FY2022
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.9x
Assets ÷ liabilities · FY2022
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+64.7%
Dilution · FY2022
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
